Search Results for: ORPHAN DRUG MARKET Drug Developers
Articles
CELL & GENE THERAPY - State of the Industry – Where is C> Headed? April 5, 2022
Bill Vincent believes if the industry wants to keep moving up the steep growth curve, then capacity and raw materials must be readily available. The innovations in therapies, platforms, and processes will all come with time, money, and increasing availability of resources.
EXECUTIVE INTERVIEW - Quotient Sciences: Unique Considerations & Challenges When Developing Palatable Pediatric Formulations November 30, 2021
Nazim Kanji, Executive Director, Pediatric Services at Quotient Sciences, discusses the unique considerations and challenges when developing palatable pediatric formulations, so that molecules can become cures, fast.
PRODUCT DEVELOPMENT STRATEGY - ESCP, Estimating Product Performance Part 4 – Building Playgrounds & Fences June 1, 2021
Josef Bossart, PhD, introduces, in a series of short articles, a qualitative model to help understand and visualize the potential of a product with prescribers, patients, and payors. This simple model can help weed out product ideas that may at first glance seem attractive but offer little potential in the real world.
CELL & GENE THERAPY - End-to-End Cell & Gene Therapy – From Development to Commercialization – Buy or Build? March 1, 2021
Aldo Romano and Emily Moran, MBA, discuss how the life science industry must bring technology solutions to the table while at the same time securing the capacity to develop and manufacture groundbreaking cures so patients and society can tap the benefits of cell and gene therapies.
PEPTIDE THERAPEUTICS - Oral Peptide Therapeutics – Opportunities Abound as Barriers Fall August 31, 2020
John S. Vrettos, PhD, says numerous technologies are currently in development that are designed to enable the oral delivery of peptides. Though each has its unique set of properties and capabilities, all must overcome key obstacles to successfully deliver peptides via the oral route.
SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: Specialized Capabilities for Small & Large Molecules June 4, 2020
Contributor Cindy H. Dubin interviews key players in the CDMO market who present case studies about how they are helping pharmaceutical and biopharma companies overcome a variety of formulation and manufacturing challenges.
SPECIAL FEATURE - Excipients: Matching Ingredients to Molecules Improves Functionality April 1, 2020
Contributor Cindy Dubin speaks with several leading excipient manufacturers on how their excipient offerings are improving drug release, solubility, taste, physical characteristics, viscosity, and more for a range of molecules.
SPECIAL FEATURE - Improving Bioavailability & Solubility: Understand Your Molecule March 3, 2020
Contributor Cindy H. Dubin asked several leading companies about how they are currently overcoming today’s most pressing bioavailability and solubility challenges for their pharma clients.
Synteract Expands Into Asia Pacific & South Africa Through Acquisition of Specialty Biometrics CRO February 6, 2020
Synteract recently acquired Clindata’s human health biometrics division to meet market demand for more adaptable biometrics services solutions. This acquisition...THERANOSTICS - The Outlook for the Theranostic Radionuclide Approach to Neuroendocrine Tumors & Other Cancers August 28, 2019
Eric P. Krenning, MD, PhD, and Rachel Levine provide a review of the evolution and development of theranostics, in general, citing the theranostic radionuclide approach to the management of neuroendocrine tumors to highlight this evolving modality.
EXECUTIVE INTERVIEW - Synteract: Advances in Pediatric Clinical Research & the Promise for the Future June 4, 2019
Dr. Martine Dehlinger-Kremer, Vice President, Pediatric Development at Synteract, reviews current and significant challenges in pediatric clinical research, advancement of regulations surrounding them, and where the industry is headed.
SPECIAL FEATURE - Prefilled Syringes & Parenteral Manufacturing: Flexibility for Faster Development April 30, 2019
Contributor Cindy H. Dubin interviews several contract manufacturers and device developers who are responsible for creating next-generation parenteral drug delivery.
SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: CDMOs Are Innovating for 21st-Century Medicine June 6, 2018
Contributor Cindy H. Dubin speaks with some of the industry’s leading CDMOs about the innovations they are developing for next-generation patient care, and how many are making investments that are enabling them to offer more services under one roof.
PEPTIDE DELIVERY - The Endometriosis Enigma – Why Can't There Be a Pill for That? June 4, 2018
Joel Tune, MBA, says for those peptide therapeutics that meet the necessary criteria, advances in formulation technologies coupled with favorable market dynamics will continue to drive interest across the entire prescription drug spectrum for safe and effective orally administered peptide therapeutics.
Avacta & Oncosec to Collaborate on Innovative Gene Delivery January 29, 2018
Avacta & Oncosec to Collaborate on Innovative Gene Delivery Avacta Group plc and OncoSec Medical Incorporated recently announced they have...AAV VECTOR MANUFACTURING - Challenges & Opportunities in the Manufacturing of AAV Vectors Used in the Delivery of Gene Therapy Treatments February 28, 2017
Daniel C. Smith, PhD, indicates there remains a clear need for improved process productivities, and the need to develop manufacturing processes that can be applied to a wide number of AAV-based viral vector therapeutic candidates.
2/13/2013 February 11, 2013
Frost & Sullivan Sees Urgent Need for Cancer Diagnostics Tests; Finds Unmet Need for Key Disorders The range of potential...1/23/2012 January 21, 2013
Amgen Invests $200 Million in Monoclonal Antibodies Amgen recently announced plans to build a new manufacturing facility in the Tuas...3/6/2012 February 29, 2012
Avanir & Concert Announce Exclusive License Agreement Avanir Pharmaceuticals, Inc. and Concert Pharmaceuticals, Inc. recently announced they have entered into...
